Public leery of third-party partnerships

Share this article:
A survey of public attitudes toward drug company partnerships with nonprofits has found skepticism of industry motives.

Among respondents to the Envision Solutions survey, 43% said pharmas fund groups like the American Heart Association and the National Kidney Foundation primarily to boost sales of their medicines.

The survey suggests a hardening of attitudes toward such partnerships. By contrast, only 10% of respondents to a similar question in a PRWeek/Barkley Public Relations poll last year said pharmas partner with non-profits primarily to boost profits.

Envision Solutions pointed to media coverage of “disease mongering” as a likely factor driving cynicism. The consultancy said the number of reports on that topic increased 775% from 2005 to 2006.

The online survey of 1,062 US adults was conducted by polling firm Kelton Research from April 10-13.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.